Toward quality improvement in cystic fibrosis newborn screening: Progress and continuing challenges

Journal of Cystic Fibrosis

Volumn 15, Issue 3, 2016, Pages 267-269

  Farrell, Philip M ^a   Sommerburg, Olaf ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

CFTR mutation; Cystic fibrosis; Immunoreactive trypsinogen; Newborn screening; Pancreatitis associate protein; Quality improvement

Indexed keywords

CONSENSUS; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; DELPHI STUDY; DNA DETERMINATION; DRIED BLOOD SPOT TESTING; EARLY DIAGNOSIS; EDITORIAL; FOLLOW UP; HUMAN; MEDICAL PRACTICE; MEDLINE; NEWBORN; NEWBORN SCREENING; PSEUDOMONAS AERUGINOSA; SCREENING TEST; TOTAL QUALITY MANAGEMENT; STANDARDS;

CYSTIC FIBROSIS; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; QUALITY IMPROVEMENT;

EID: 84969543332     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.04.008     Document Type: Editorial

References (21)

1. Castellani C., Massie J., Sontag M., Southern K.W. Newborn screening for cystic fibrosis. Lancet Respir Med Apr 1 2016, [pii: S2213-2600(16)00053-9]. 10.1016/S2213-2600(16)00053-9.
2. Gregg R.G., Wilfond B.S., Farrell P.M., Laxova A., Hassemer D., Mischler E.H. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet 1993, 52:616-626.
3. Farrell P., Kosorok M., Rock M., et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics 2001, 107:1-12.
4. Grosse S.D., Boyle C.A., Botkin J.R., et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004, 53(RR-13):1-36.
5. Campbell P.W., White T.B. Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes. J Pediatr 2005, 147:S2-S5.
6. Mak D., Jenna Sykes J., Stephenson A., Larry Lands L. The benefits of newborn screening for cystic fibrosis: the Canadian experience. J Cyst Fibros 2016, 15:302-308.
7. Bergougnoux A., Boureau-Wirth A., Rouzier C., Altieri J.P., Verneau F., Larrieu L., et al. False positive newborn screening result due to a complex allele carrying two frequent CF-causing variants. J Cyst Fibros 2016, 15:309-312.
8. Ren C.L., Fink A.K., Petren K., Borowitz D.S., McColley S.A., Sanders D.B., et al. Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening. Pediatrics 2015, 135:e1386-e1392.
9. Barben J., Rueegg C.S., Jurca M., Spalinger J., CE Kuehni, Swiss Cystic Fibrosis Screening Group Measurement of fecal elastase improves performance of newborn screening for cystic fibrosis. J Cyst Fibros 2016, 15:313-317.
10. Borowitz D., Baker S.S., Duffy L., Baker R.D., Fitzpatrick L., Gyamfi J., et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004, 145:322-326.
11. O'Sullivan B.P., Baker D., Leung K.G., Reed G., Baker S.S., Borowitz D. Evolution of pancreatic function during the first year in infants with cystic fibrosis. J Pediatr 2013, 162:808-812.
12. Lundman E., Gaup H.J., Bakkeheim E., Olafsdottir E.J., Rootwelt T., Storrøsten O.T., et al. Implementation of newborn screening for cystic fibrosis in Norway. Results from the first three years. J Cyst Fibros 2016, 15:318-324.
13. Munck A., Mayell S.J., Winters V., Shawcross A., Derichs N., Parad R., et al. Cystic fibrosis screen positive, inconclusive diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros 2015, 14:706-713.
14. Kharrazi M., Yang J., Bishop T., Lessing S., Young S., Graham S., et al. Newborn screening for cystic fibrosis in California. Pediatrics 2015, 136(6):1062-1072.
15. Sontag M.K., Lee R., Wright D., Freidenberg D., Sagel S.D. Improving the sensitivity and positive predictive value in a Cystic Fibrosis newborn screening program using a repeat immunoreactive trypsinogen and genetic analysis. J Pediatr 2016 Apr 27, pii: S0022-3476(16)00427-3, [Epub ahead of print] PMID: 27131402. 10.1016/j.jpeds.2016.03.046.
16. Vernooij-van Langen A.M., Loeber J.G., Elvers B., Triepels R.H., Gille J.J., Van der Ploeg C.P., et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax 2012, 67:289-295.
17. Sarles J., Berthézène P., Le Louarn C., Somma C., Perini J.M., Catheline M., et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 2005, 147:302-305.
18. Sarles J., Giorgi R., Berthezene P., Munck A., Cheillan D., Dagorn J.C., et al. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP. J Cyst Fibros 2014, 13:384-390.
19. Sommerburg O., Hammermann J., Lindner M., Stahl M., Muckenthaler M., Kohlmueller D., et al. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany. Pediatr Pulmonol 2015, 50:655-664.
20. Rock M.J., Levy H., Zaleski C., Farrell P.M. Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening. Pediatr Pulmonol 2011, 46:1166-1174.
21. Castellani C., Southern K.W., Brownlee K., et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009, 8:153-173.